Stumbled upon this article today as I am trying to research more about my dads cancer that has now become resistant to hormone therapy. It explicitly states that “MCRPC is associated with poorer outcomes, with most patients dying within two years of diagnosis (4).Apr 14, 2022”
I don’t know if there’s a part of this I don’t want to accept or if I’m being naive, but I don’t want to believe that your life expectancy becomes SIGNIFICANTLY shorter once castration resistance settles in, especially if you are metastatic. What are doctors doing currently for metastatic prostate cancer patients?
There’s lots of info circulating the forum of ways it might occur or how to prevent it, but what can be done when you’re metastatic AND castrate resistant?
Most therapies and hundreds of clinical trials are available for patients who are metastatic and castration-resistant. So far, these drugs have been approved:
Taxotere, Jevtana, Zytiga, Xtandi, Pluvicto, Xofigo, Provenge, Lynparza & Rubraca (for BRCA+), and Keytruda (for MSI-hi/dMMR) with all sorts of combinations and sequences possible.
There are other therapies after chemo such as xofigo, combination of therapies, cabazitaxel, platinum compounds, Lu 177 PSMA, olaparib, rucaparib, keytruda, immunotherapies and protacs in clinical trials etc.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
BAT therapy - NIH article
1/4 dose enzalutamide for MCRPc working for 4 years in 87 yr. old
New Cancer drug (apalutamide) approved for patients with non-mCRPC
What is mCRPC
